Chemoinformaics analysis of (Z)-OCT-2-EN-1-OL
| Molecular Weight | 128.215 | nRot | 5 |
| Heavy Atom Molecular Weight | 112.087 | nRig | 10 |
| Exact Molecular Weight | 128.12 | nRing | 0 |
| Solubility: LogS | -1.616 | nHRing | 0 |
| Solubility: LogP | 2.314 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 25 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 9 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 24.8307 |
| nHD | 1 | BPOL | 16.0513 |
| QED | 0.783 |
| Synth | 1.825 |
| Natural Product Likeliness | -0.341 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.004 |
| Pgp-sub | 0.096 |
| HIA | 0.004 |
| CACO-2 | -4.478 |
| MDCK | 0.00000898 |
| BBB | 0.99 |
| PPB | 0.431185 |
| VDSS | 2.916 |
| FU | 0.58481 |
| CYP1A2-inh | 0.249 |
| CYP1A2-sub | 0.955 |
| CYP2c19-inh | 0.039 |
| CYP2c19-sub | 0.945 |
| CYP2c9-inh | 0.006 |
| CYP2c9-sub | 0.728 |
| CYP2d6-inh | 0.901 |
| CYP2d6-sub | 0.938 |
| CYP3a4-inh | 0.013 |
| CYP3a4-sub | 0.309 |
| CL | 8.254 |
| T12 | 0.666 |
| hERG | 0.173 |
| Ames | 0.018 |
| ROA | 0.932 |
| SkinSen | 0.881 |
| Carcinogencity | 0.055 |
| EI | 0.176 |
| Respiratory | 0.978 |
| NR-Aromatase | 0.045 |
| Antiviral | No |
| Prediction | 0.955514 |